{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:02:46Z","timestamp":1776135766380,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cpcardiol.2021.100852","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:09:28Z","timestamp":1617736168000},"page":"100852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Dina","family":"Abushanab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2021.100852_bib0001","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. Eighth edition 2017. Available at: https:\/\/www.idf.org\/e-library\/epidemiology-research\/diabetes-atlas\/134-idf-diabetes-atlas-8th-edition.html. Accessed 14 March 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0002","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0003","unstructured":"BIG HEARTS BRILIANT MINDS. Impact report 2018. Available at: https:\/\/baker.edu.au\/-\/media\/documents\/who-we-are\/corporate-reports\/baker-institute-impact-report-2018.pdf. Accessed 20 June 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-0042-103683","article-title":"Predictions burden of diabetes and economics cost: contributing risk factors of changing disease prevalence and its pandemic impact to qatar","volume":"124","author":"Bener","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0005","unstructured":"Innovative Approaches to Prevention Tackling the Global Burden of Cardiovascular Disease. Report of the WISH Cardiovascular Disease Forum 2016. Available at: https:\/\/www.wish.org.qa\/wp-content\/uploads\/2018\/01\/IMPJ4495_WISH_CArdio_Disease_181116_WEB.pdf. Accessed 20 June 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0006","unstructured":"Qatar's Forth National Human Development Report. Realising Qatar National Vision 2030 the right to development. 2015. Available at: http:\/\/hdr.undp.org\/sites\/default\/files\/qatar_nhdr4_english_15june2015.pdf. Accessed 10 September 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0007","unstructured":"Diabetes. Ministry of Public Health. Available at: https:\/\/phs.moph.gov.qa\/data\/diabetes\/. Accessed 30 November 2020."},{"issue":"17","key":"10.1016\/j.cpcardiol.2021.100852_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12963-019-0200-1","article-title":"Preventing type 2 diabetes mellitus in Qatar by reducing obesity, smoking, and physical inactivity: mathematical modeling analyses","volume":"30","author":"Awad","year":"2019","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0009","unstructured":"National Health Strategy 2018-2022. Available at: https:\/\/lc.ucalgary.edu.qa\/ld.php?content_id=41255610. Accessed 23 November 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0010","unstructured":"The Royal Australian College of General Practitioners. General practice management of type 2 diabetes 2016\u201318. Available at: https:\/\/www.racgp.org.au\/FSDEDEV\/media\/documents\/Clinical%20Resources\/Guidelines\/Diabetes\/General-practice-management-of-type-2-diabetes_1.pdf. Accessed 27 March 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0011","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0013","doi-asserted-by":"crossref","unstructured":"T\u00e4ger T, Atar D, Agewall S, et al. comparative efficacy of sodium-glucose cotransporter-2 Inhibitors (SGLT2i) for cardiovascular outcomes in Type 2 Diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev. 2020.","DOI":"10.1007\/s10741-020-09954-8"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.22259\/2638-4981.0201002","article-title":"Role of Combination Therapy with SGLT2 Inhibitor with Metformin as Initial Treatment for Type2 DiabetesAdvantages of Oral Fixed Drug Pill Like Empagliflozin\/Metformin in Patients with Cardiovascular and Renal Risk-A Short Communication","volume":"2","author":"Kaur","year":"2019","journal-title":"Archives of Diabetes and Endocrine System"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0015","unstructured":"Qatar National Diabetes Strategy. Preventing Diabetes Together 2016-2022. Available at: https:\/\/www.moph.gov.qa\/Style%20Library\/MOPH\/Files\/strategies\/Qatar%20National %20Diabetes%20Strategy\/12477%20PA%20National%20Diabetes%20Eng%20.compressed.pdf. Accessed 30 November 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0016","unstructured":"Thresholds for the cost\u2013effectiveness of interventions: alternative approaches. Available at: https:\/\/www.who.int\/bulletin\/volumes\/93\/2\/14-138206\/en\/#:\u223c:text=Benchmark%20interventions,-Originally%20proposed%20by&text=In%20the%20USA %2C%20for%20example,dialysis%20for%20chronic%20renal%20disease.&text=This%20threshold%20has%20recently%20been,150%20000%20per %20QALY%20 gained. Accessed 10 September 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/heapol\/czaa073","article-title":"On discount rates for economic evaluations in global health","volume":"35","author":"Haacker","year":"2020","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0018","unstructured":"Institute for Health Metrics and Evaluation. Available at: http:\/\/www.healthdata.org\/about. Accessed 30 September 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0020","unstructured":"Ministry of Development Planning and Statistics. Births & Deaths In the State of Qatar, 2016. Available at: https:\/\/www.psa.gov.qa\/en\/statistics\/Statistical%20Releases\/Population\/BirthsDeaths\/2016\/Birth_death_2016_EN.pdf. Accessed 10 September 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","article-title":"Population trends of recurrent coronary heart disease event rates remain high","volume":"4","author":"Briffa","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0022","series-title":"Oxford","article-title":"Decision Modeling for Health Economics Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0023","unstructured":"Hamad Medical Corporation. Available at: https:\/\/www.hamad.qa\/EN\/Pages\/default.aspx. Accessed 10 November 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jdiacomp.2014.12.009","article-title":"Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities","volume":"29","author":"Candrilli","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0025","unstructured":"Health spending. Available at: https:\/\/data.oecd.org\/healthres\/health-spending.htm. Accessed 15 October 2020"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0026","unstructured":"Qatar - Gross domestic product per capita based on purchasing-power-parity in current prices. Available at: https:\/\/knoema.com\/atlas\/Qatar\/GDP-per-capita-based-on-PPP#:\u223c:text=Qatar%20%2D%20Gross%20domestic%20product%20per,power%2Dparity%20in%20current%20prices&text=GDP%20per%20capita%20based %20on%20PPP%20of%20Qatar%20increased%20from,average%20annual%20rate%20of%202.47%25. Accessed 15 October 2020"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0027","doi-asserted-by":"crossref","first-page":"w14626","DOI":"10.4414\/smw.2018.14626","article-title":"Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight","volume":"148","author":"Ademi","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0028","unstructured":"Qatar: Inflation rate from 1984 to 2021. Available at: https:\/\/www.statista.com\/statistics\/379995\/inflation-rate-in-qatar\/. Accessed 15 October 2020."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0029","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0030","doi-asserted-by":"crossref","first-page":"231e50","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.cpcardiol.2021.100852_bib0031","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1038\/s41598-019-43052-6","article-title":"Assessment of dapagliflozin effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes mellitus in a qatari population","volume":"3","author":"Al AdAwi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0032","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dme.14076","article-title":"Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial","volume":"36","author":"Kansal","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0033","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40261-018-0620-x","article-title":"Cost-effectiveness of empagliflozin for the treatment of patients with Type 2 Diabetes mellitus at increased cardiovascular risk in Greece","volume":"38","author":"Gourzoulidis","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0034","first-page":"3256","article-title":"Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with Type 2","volume":"9","author":"Chin","year":"2019","journal-title":"Diabetes. Sci Rep."},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob Health Action"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0036","series-title":"PPP (current international $)","year":"2020"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0037","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-12-58","article-title":"Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease","volume":"12","author":"Mielck","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cpcardiol.2021.100852_bib0038","unstructured":"Qatar GDP. Available at: https:\/\/tradingeconomics.com\/qatar\/gdp. Accessed 10 November 2020."}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:57:35Z","timestamp":1758938255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280621000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0146280621000670"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100852","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100852"}}